Bioxyne's (ASX:BXN) Breathe Life Sciences subsidiary dispatched its second shipment of Good Manufacturing Practice (GMP) MDMA capsules to the Victorian Government's Eastern Health department, according to a Wednesday filing with the Australian bourse.

The shipment will facilitate a clinical trial focused on MDMA-assisted psychotherapy for patients with co-occurring post-traumatic stress disorder and borderline personality disorder, the filing said.